ITPR3 and non-small cell lung carcinoma: Indeed, treatments with quisinostat78, a second-generation HDACi, resulted in strong activation of SMARCA2 with concomitant elevation of IP3R3 at both mRNA and protein levels in SCCOHT (Supplementary Fig. 13) and SMARCA4/2-deficient NSCLC cancer cells (Fig. 6a, b).